Jianguang Gong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jianguang Gong has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Bin Zhu
Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China
2 shared publications - Biao Huang
College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China
1 shared publication - Bo Lin
Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China (Xu, Zou, Lin, Zhu, and Gong)
1 shared publication Chen Lingli
College of Life Sciences and Medicine Zhejiang Sci‐Tech University Hangzhou China
1 shared publication- He Huang
Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication Jianlan Zheng
Urology & Nephrology Center, Department of Nephrology, Affiliated People’s Hospital, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Hangzhou, People’s Republic of China
1 shared publication
Latest Publications
- 29 May 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (8) , 1691-1694
A case of normolipidemic lipoprotein glomerulopathy due to the APOE Kyoto variant
- 29 May 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (8) , 1691-1694
A case of normolipidemic lipoprotein glomerulopathy due to the APOE Kyoto variant
- Open Access
- 4 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Astragaloside IV attenuates uremia-induced myocardial injury by inhibiting autophagy via ATF4
Background Cardiovascular diseases (CVDs) are one of the primary causes of mortality in patients with uremia. The therapeutic value of intravenous Astragaloside (AS-IV) in the treatment of CVDs has been widely recognized. However, whether AS-IV treats CVDs complicated by uremia remains unknown. This study aimed to determine the effects and potential mechanisms of AS-IV in the treatment of CVDs associated with uremia. Methods The 5/6 nephrectomized mouse model and uremic serum (US)-induced myocardial injury model of H9C2 cells were established in this study. Various techniques, including echocardiography, ELISA, TUNEL assay, flow cytometry, Western blotting, immunofluorescence, transmission electron microscopy, and qRT-PCR, were employed to investigate the effects of AS-IV on uremia-associated myocardial injury and determine its impact on autophagy and related signaling pathways. An ATF4 inhibitor and plasmid transfection techniques were used to modulate ATF4 expression and investigate the role of ATF4 in the protective effects of AS-IV on myocardial injury. Results AS-IV significantly improved cardiorenal function and attenuated uremia-associated cardiomyocyte apoptosis in 5/6 nephrectomized mice. Autophagy was significantly activated, and ATF4 expression was increased in 5/6 nephrectomized mice and uremic toxin-treated cardiomyocytes. AS-IV also significantly inhibited ATF4 expression and cardiomyocyte autophagy. Inhibition of ATF4 expression reduced cardiomyocyte apoptosis, while ATF4 overexpression significantly attenuated the cardioprotective effects of AS-IV. AS-IV significantly activated the PI3K pathway, while modulation of ATF4 expression affected AS-IV-mediated activation of the PI3K pathway. Conclusions AS-IV ameliorated uremia-associated myocardial injury by suppressing ATF4 expression and regulating cardiomyocyte autophagy. The PI3K pathway may modulate autophagy after treatment with AS-IV.
- 4 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessAstragaloside IV attenuates uremia-induced myocardial injury by inhibiting autophagy via ATF4
Background Cardiovascular diseases (CVDs) are one of the primary causes of mortality in patients with uremia. The therapeutic value of intravenous Astragaloside (AS-IV) in the treatment of CVDs has been widely recognized. However, whether AS-IV treats CVDs complicated by uremia remains unknown. This study aimed to determine the effects and potential mechanisms of AS-IV in the treatment of CVDs associated with uremia. Methods The 5/6 nephrectomized mouse model and uremic serum (US)-induced myocardial injury model of H9C2 cells were established in this study. Various techniques, including echocardiography, ELISA, TUNEL assay, flow cytometry, Western blotting, immunofluorescence, transmission electron microscopy, and qRT-PCR, were employed to investigate the effects of AS-IV on uremia-associated myocardial injury and determine its impact on autophagy and related signaling pathways. An ATF4 inhibitor and plasmid transfection techniques were used to modulate ATF4 expression and investigate the role of ATF4 in the protective effects of AS-IV on myocardial injury. Results AS-IV significantly improved cardiorenal function and attenuated uremia-associated cardiomyocyte apoptosis in 5/6 nephrectomized mice. Autophagy was significantly activated, and ATF4 expression was increased in 5/6 nephrectomized mice and uremic toxin-treated cardiomyocytes. AS-IV also significantly inhibited ATF4 expression and cardiomyocyte autophagy. Inhibition of ATF4 expression reduced cardiomyocyte apoptosis, while ATF4 overexpression significantly attenuated the cardioprotective effects of AS-IV. AS-IV significantly activated the PI3K pathway, while modulation of ATF4 expression affected AS-IV-mediated activation of the PI3K pathway. Conclusions AS-IV ameliorated uremia-associated myocardial injury by suppressing ATF4 expression and regulating cardiomyocyte autophagy. The PI3K pathway may modulate autophagy after treatment with AS-IV.
- Open Access
- 23 July 2022
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (9)
Establishment of a time‐resolved immunoassay for acute kidney injury based on the detection of Kim‐1
Aim: To establish a highly sensitive time‐resolved fluorescence immunoassay (TRFIA) of kidney injury molecule‐1 (Kim‐1) and evaluate its clinical value in acute kidney injury (AKI).Methods: The Kim‐1‐TRFIA was established by the double‐antibody sandwich method, and the method was evaluated. The established Kim‐1‐TRFIA was used to detect the concentration of Kim‐1 in the serum of healthy controls and patients with AKI.Results: The optimal coating antibody concentration and optimal Eu3+‐labeled antibody dilution ratio for Kim‐1‐TRFIA are 1 μg/ml and 1:140, respectively. The linear range is 42.71–4666.69 pg/ml. The intra‐ and inter‐assay coefficients of variation are p < 0.001). Staging patients with AKI by glomerular filtration rate shows that the serum concentration of Kim‐1 increases significantly with increasing disease severity (p < 0.05).Conclusion: A highly sensitive Kim‐1‐TRFIA was established. With this immunoassay, a good differential diagnosis can be made, and healthy people and AKI patients can be differentiated by detecting the concentration of Kim‐1 in the serum. Moreover, the severity of AKI patients can be determined.
- 23 July 2022
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (9)
Open AccessEstablishment of a time‐resolved immunoassay for acute kidney injury based on the detection of Kim‐1
Aim: To establish a highly sensitive time‐resolved fluorescence immunoassay (TRFIA) of kidney injury molecule‐1 (Kim‐1) and evaluate its clinical value in acute kidney injury (AKI).Methods: The Kim‐1‐TRFIA was established by the double‐antibody sandwich method, and the method was evaluated. The established Kim‐1‐TRFIA was used to detect the concentration of Kim‐1 in the serum of healthy controls and patients with AKI.Results: The optimal coating antibody concentration and optimal Eu3+‐labeled antibody dilution ratio for Kim‐1‐TRFIA are 1 μg/ml and 1:140, respectively. The linear range is 42.71–4666.69 pg/ml. The intra‐ and inter‐assay coefficients of variation are p < 0.001). Staging patients with AKI by glomerular filtration rate shows that the serum concentration of Kim‐1 increases significantly with increasing disease severity (p < 0.05).Conclusion: A highly sensitive Kim‐1‐TRFIA was established. With this immunoassay, a good differential diagnosis can be made, and healthy people and AKI patients can be differentiated by detecting the concentration of Kim‐1 in the serum. Moreover, the severity of AKI patients can be determined.
- Top Cited PapersOpen Access
- 15 March 2019
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 10 (1) , 1-15
Exosome secreted from adipose-derived stem cells attenuates diabetic nephropathy by promoting autophagy flux and inhibiting apoptosis in podocyte
It is confirmed that adipose-derived stem cells (ADSCs) transplantation effectively relieves kidney fibrosis and type 2 diabetes disease in mice. Currently, exosome from urine-derived stem cells (USCs) can protect type 1 diabetes-mediated kidney injury and attenuate podocyte damage in diabetic nephropathy (DN). Exosome derived from USCs has evolved into the strategy for DN treatment, but the role of ADSCs-derived exosome (ADSCs-Exo) in DN remains unclear. The present study is aimed to investigate the therapeutic action and molecular mechanism of ADSCs-derived exosome on DN. ADSCs and exosome were authenticated by immunofluorescence and flow cytometry. Morphology and the number of exosome were evaluated by electron microscope and Nanosight Tracking Analysis (NTA), respectively. Cell apoptosis was assessed using flow cytometry. Podocyte autophagy and signaling transduction were measured by immunofluorescence and immunoblotting. Dual Luciferase Reporter assay was employed to detect the regulatory relationship between miR-486 and Smad1. ADSCs-Exo attenuated spontaneous diabetes by reducing levels of urine protein, serum creatinine (Scr), blood urea nitrogen (BUN), and podocyte apoptosis in mice. In in vitro experiment, ADSCs-Exo also reversed high glucose-induced decrease of cell viability and the increase of cell apoptosis in MPC5 cells. In terms of mechanism, ADSCs-Exo could enhance autophagy flux and reduce podocyte injury by inhibiting the activation of mTOR signaling in MPC5 and spontaneous diabetic mice. Eventually, we found that miR-486 was the key factors in ADSCs and in the process of ADSCs-Exo-mediated improvement of DN symptom in vivo and in vitro. miR-486 reduced Smad1 expression by target regulating Smad1 whose reduction could inhibit mTOR activation, leading to the increase of autophagy and the reduction of podocyte apoptosis. In conclusion, we illustrated that ADSCs-Exo vividly ameliorated DN symptom by enhancing the expression of miR-486 which led to the inhibition of Smad1/mTOR signaling pathway in podocyte. Possibly, ADSCs-Exo was used as a main therapeutic strategy for DN in future.
- 15 March 2019
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 10 (1) , 1-15
Top Cited PapersOpen AccessExosome secreted from adipose-derived stem cells attenuates diabetic nephropathy by promoting autophagy flux and inhibiting apoptosis in podocyte
It is confirmed that adipose-derived stem cells (ADSCs) transplantation effectively relieves kidney fibrosis and type 2 diabetes disease in mice. Currently, exosome from urine-derived stem cells (USCs) can protect type 1 diabetes-mediated kidney injury and attenuate podocyte damage in diabetic nephropathy (DN). Exosome derived from USCs has evolved into the strategy for DN treatment, but the role of ADSCs-derived exosome (ADSCs-Exo) in DN remains unclear. The present study is aimed to investigate the therapeutic action and molecular mechanism of ADSCs-derived exosome on DN. ADSCs and exosome were authenticated by immunofluorescence and flow cytometry. Morphology and the number of exosome were evaluated by electron microscope and Nanosight Tracking Analysis (NTA), respectively. Cell apoptosis was assessed using flow cytometry. Podocyte autophagy and signaling transduction were measured by immunofluorescence and immunoblotting. Dual Luciferase Reporter assay was employed to detect the regulatory relationship between miR-486 and Smad1. ADSCs-Exo attenuated spontaneous diabetes by reducing levels of urine protein, serum creatinine (Scr), blood urea nitrogen (BUN), and podocyte apoptosis in mice. In in vitro experiment, ADSCs-Exo also reversed high glucose-induced decrease of cell viability and the increase of cell apoptosis in MPC5 cells. In terms of mechanism, ADSCs-Exo could enhance autophagy flux and reduce podocyte injury by inhibiting the activation of mTOR signaling in MPC5 and spontaneous diabetic mice. Eventually, we found that miR-486 was the key factors in ADSCs and in the process of ADSCs-Exo-mediated improvement of DN symptom in vivo and in vitro. miR-486 reduced Smad1 expression by target regulating Smad1 whose reduction could inhibit mTOR activation, leading to the increase of autophagy and the reduction of podocyte apoptosis. In conclusion, we illustrated that ADSCs-Exo vividly ameliorated DN symptom by enhancing the expression of miR-486 which led to the inhibition of Smad1/mTOR signaling pathway in podocyte. Possibly, ADSCs-Exo was used as a main therapeutic strategy for DN in future.